Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma

Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.

Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.